Compare ALIT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | VALN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.0M | 855.8M |
| IPO Year | N/A | 2021 |
| Metric | ALIT | VALN |
|---|---|---|
| Price | $1.49 | $10.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $4.70 | ★ $15.75 |
| AVG Volume (30 Days) | ★ 10.4M | 19.5K |
| Earning Date | 02-19-2026 | 11-20-2025 |
| Dividend Yield | ★ 10.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,289,000,000.00 | $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | $1.43 | $12.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $1.48 | $4.56 |
| 52 Week High | $7.66 | $12.25 |
| Indicator | ALIT | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 22.15 | 54.28 |
| Support Level | $1.52 | $9.62 |
| Resistance Level | $1.94 | $10.32 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 1.89 | 62.50 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.